BioCryst Pharmaceuticals | BCRX - Assets


BioCryst Pharmaceuticals reported $557.85M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Chugai Pharma JPY 2.45T 184.81B Jun/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
DBV Technologies USD 223.2M 43.2M Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026